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Pregnancy-associated malaria is caused by Plasmodium falciparum malaria parasites binding specifically to chondroitin
sulfate A in the placenta. This sequestration of parasites is a major cause of low birth weight in infants and anemia in
the mothers. VAR2CSA, a polymorphic multi-domain protein of the PfEMP1 family, is the main parasite ligand for CSA
binding, and identification of protective antibody epitopes is essential for VAR2CSA vaccine development. Attempts to
determine the crystallographic structures of VAR2CSA or its domains have not been successful yet. In this study, we
propose 3D models for each of the VAR2CSA DBL domains and we show that regions in the fold of VAR2CSA inter-
domain 2 and a PfEMP1 CIDR domain seem to be homologous to the EBA-175 and Pka-DBL fold. This suggests that ID2
could be a functional domain. We also identify regions of VAR2CSA present on the surface of native VAR2CSA by
comparing reactivity of plasma containing anti-VAR2CSA antibodies in peptide array experiments before and after
incubation with native VAR2CSA. By this method we identify conserved VAR2CSA regions targeted by antibodies that
react with the native molecule expressed on infected erythrocytes. By mapping the data onto the DBL models we
present evidence suggesting that the S1þS2 DBL sub-domains are generally surface-exposed in most domains,
whereas the S3 sub-domains are less exposed in native VAR2CSA. These results comprise an important step towards
understanding the structure of VAR2CSA on the surface of CSA-binding infected erythrocytes.
Citation: Andersen P, Nielsen MA, Resende M, Rask TS, Dahlba ¨ck M, et al. (2008) Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA. PLoS
Pathog 4(2): e42. doi:10.1371/journal.ppat.0040042
Introduction
Adhesion of Plasmodium falciparum parasite-infected eryth-
rocytes (IE) to the vascular bed is mediated by P. falciparum
erythrocyte membrane protein 1 (PfEMP1), which interacts
speciﬁcally with receptors on the vascular endothelium or
placenta [1,2]. The adhesion mechanism is thought to be
developed by the parasite to avoid ﬁltering through the
spleen, where erythrocytes infected with late stage asexual
parasites are removed from the circulation [3]. Antibodies
that target PfEMP1 and abrogate binding are believed to be
important mediators of acquired malaria immunity (re-
viewed in [4]). Pregnancy-associated malaria (PAM) is caused
by P. falciparum sequestering in the placenta by binding to
chondroitin sulfate A (CSA), which is a type of glycosami-
noglycan attached on the surface of syncytiotrophoblasts [5].
Women suffering from PAM develop antibodies which
protect them and their offspring during subsequent preg-
nancies [6]. These protective antibodies are thought to
recognize a relatively conserved antigen as plasma and
parasites from pregnant women from different malaria
endemic areas cross-react [7]. The PfEMP1 variant mediating
placental binding was recently discovered and named
VAR2CSA [2,8]. The extracellular part of VAR2CSA consists
of six Duffy-binding-like (DBL) domains, a large inter-
domain (ID2) and a C-terminal region predicted to be
cytoplasmic. Most PfEMP1 molecules, but not VAR2CSA,
contain two cysteine-rich interdomain regions (CIDR do-
mains) [9,10]. Some CIDR domains bind to CD36 [11] and
they have been described as degenerated DBL domains [12]
despite a very low sequence homology between DBL and
CIDR domains.
The invasion of erythrocytes and the subsequent adhesion
of IE to vascular endothelium or placenta are key events in
the asexual life cycle of P. falciparum and thus of major
importance for the virulence of this parasite. Erythrocyte
invasion is mediated by proteins belonging to the erythrocyte
binding ligand family (EBL) and in P. falciparum the
erythrocyte binding antigen (EBA)-175 is the best described
EBL protein. EBA-175 has some similarity to VAR2CSA:
Firstly, EBA-175 contains two DBL domains (called F1 and
F2). Secondly, the EBA-175 DBL domains bind glycans on the
sialylated glycophorin A on the erythrocyte surface [13]. The
monomeric structure of EBA-175 has been determined by X-
ray crystallography and the primary features of the two DBL
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hairpin [14]. EBA-175 also crystallized as a dimer, and the
structure of this complex showed that the DBL domains of
EBA-175 interacted in a reverse handshake orientation [14].
The simian malaria parasite, Plasmodium knowlesi invades
erythrocytes through the host receptor ‘‘Duffy antigen
receptor for chemokines’’ (DARC) [15]. This interaction is
also mediated by a parasite-encoded DBL-containing protein,
Pka-DBL, and the crystal structure of Pka-DBL has been
shown to be very similar to PfEBA-175 despite extensive
sequence variation [16]. Based on the structure of Pka-DBL,
the DBL domain could be divided into three sub-domains
named S1–S3 which are connected by short linkers. Both the
glycan binding site of PfEBA-175 and the DARC binding site
of Pka-DBL are predominantly located in S1 and S2 [14,16].
With the aim of making a vaccine that can reverse or
inhibit parasite binding in the placenta, considerable effort
has been put into deﬁning the speciﬁc part/parts of
VAR2CSA that bind to CSA (reviewed in [17]). The best way
of determining this interaction would be to produce the
extracellular part of VAR2CSA and co-crystallize this multi-
domain protein with CSA. However, it is very difﬁcult to
express such a large protein and previous attempts to
crystallize even single VAR2CSA DBL domains have failed.
Thus, novel methods are required to generate testable models
and hypotheses on the overall 3D structure of PfEMP1
molecules. The DBL domains of PfEMP1 are often illustrated
as ‘‘pearls on a string’’ and vaccine development strategies are
focusing on the VAR2CSA DBL domains as single entities in a
larger protein. We have recently published data showing a
structural model of VAR2CSA DBL3X and mapped areas of
DBL3X that are surface-exposed and reactive to naturally
acquired antibodies on the native protein [18]. In this
previous study, we showed that most variable regions of
DBL3X are located in ﬂexible loops or surface-exposed parts
of the model. These ﬁndings were supported by an analysis of
106 VAR2CSA sequences which was published recently [19],
and showed that polymorphic sites in general are situated in
ﬂexible loop regions or other surface exposed areas of
VAR2CSA DBL structure models.
In this study, we modeled the remaining ﬁve 3D7 VAR2CSA
DBL domains, the VAR2CSA inter-domain 2 (ID2) and a
number of CIDR domains from different PfEMP1 molecules
to get insight into the location of epitopes in the whole
VAR2CSA molecule. The models indicate that DBL domains
contain features that are structurally conserved. Furthermore
it appears that there is homology between the ID2, CIDR and
part of the resolved structures of the DBL fold. By absorbing
antibodies on native VAR2CSA on the surface of IE and
comparing antibody reactivity on a VAR2CSA peptide array
before and after absorption, we deﬁne areas of the VAR2CSA
molecule which may be accessible to antibodies in the native
protein. For all domains we ﬁnd that relatively invariant parts
are recognized and surface-exposed in the native VAR2CSA.
The surface-exposed epitopes on the six VAR2CSA domains
are largely found within S1 and S2, whereas S3 appears to be
hidden in the complete VAR2CSA structure. This ﬁnding is
interesting because it leads to the ﬁrst suggestions about the
overall structure of VAR2CSA; based on these data we discuss
the domain architecture of VAR2CSA and suggest a model
where the protein is surface-exposed as a globular or
multimerized structured protein stabilized by long a-helices
in the S3 region.
Results/Discussion
Modeling of the VAR2CSA DBL Domains
The 3-D structures of the 3D7 VAR2CSA DBL domains
(Figure 1) were modeled using the HHpred server [20]
developed for low-homology modeling. HHpred template
searches conﬁrmed that the determined structures of the P.
falciparum EBA-175 DBL domains F1 and F2 and the P.
knowlesi DBL domain Pka-DBL [14,16] could be used as
templates for modeling (HHpred probability scores were all
100%), although the sequence identity between the VAR2-
CSA DBL domains and templates was between 16–20% (see
modeling details in Table S1). The determined structures of
the two EBA-175 DBL domains each contain a region where
structural information is missing and the structure of Pka-
DBL has four such regions (Table S1 and Figure 2). In
crystallographic experiments, the local occurrence of missing
structural information indicates regions of ﬂexibility and
loosely deﬁned secondary structure. For Pka-DBL, the
regions of missing structural information were used to divide
the DBL fold into the subdomains S1–S3 [14] and we adapted
a similar classiﬁcation for the VAR2CSA DBL domains
(Figures 1 and 2). VAR2CSA residues corresponding to
regions of missing structural information in the templates
were modeled as insertions relative to the template structure.
The structure of such inserted regions is difﬁcult to predict
correctly [21]. Secondary structure predictions using the
PSIPRED method [22] is part of the HHpred modeling
protocol. The prediction results are divided into helix, strand
and coil, where the coil class consists of secondary structure
types mostly found in loops. Interestingly, the template
regions of missing structural information aligned with
VAR2CSA DBL sequences predicted to have coil secondary
structure. In general, the VAR2CSA sequence variation is
high within these regions (Figure 2). Taken together, this
suggests that most of the variable regions in all VAR2CSA
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Author Summary
Individuals living in areas with high Plasmodium falciparum trans-
mission acquire immunity to malaria over time and adults have
markedly reduced risk of getting severe disease. However, pregnant
women constitute an important exception, and they become more
susceptible to malaria during pregnancy. This so called pregnancy-
associated malaria (PAM) has severe consequences for both mother
and child, and a vaccine would save hundreds of thousands of lives
each year. PAM is caused by P. falciparum–infected red blood cells
that bind to receptors in the placenta. By binding to the placental
tissue, the parasites avoid being filtered though the spleen where
they would have been killed. The protein mediating this placental
binding is a very large multidomain and variant protein named
VAR2CSA. Using structural modeling of VAR2CSA and antibody
reagents from women who have had PAM, we show that antibodies
tend to bind in similar regions, on one side of the individual
VAR2CSA domains. In addition, we show that highly conserved parts
of this variant protein are accessible for antibodies. This finding
correlates with epidemiological data showing that woman acquire
immunity towards PAM relatively fast, and the identification of these
epitopes is thus a major step towards a protective vaccine.DBL domains form a variety of ﬂexible loops with different
conformations. These results support the ﬁndings reported
by Bockhorst et al., who recently reported a similar tendency
in structural models of VAR2CSA DBL2X and DBL3X [19].
From a structural perspective these ﬁndings makes biological
sense because the overall DBL fold could be preserved while
surface-exposed parts and loop areas which are possibly less
important for stabilization of the fold, would have more
freedom to mutate.
Evaluation of the VAR2CSA DBL Structure Models
The quality of a structure model obviously has a
pronounced effect on the information that can be deduced
from the model. We used the automated structure analysis
tool ANOLEA [23] for evaluation, and Z-scores ranging from
5.00 to 9.61 with 52%–68% high-energy residues were
obtained. The results indicated that the quality was lowest
in the loop regions. Analysis using Verify3d [24] resulted in a
similar conclusion (data not shown). Since these results did
Figure 1. Structure Models of the VAR2CSA DBL Domains
The experimental structures of the template EBA-175 and Pka-DBL domains are shown in the first row, and DBL models are shown in the middle and
last rows. Sub-domains 1–3 of Pka-DBL (Pka-DBL) are colored in blue, green, and yellow, respectively. Cysteines in all domains are highlighted in red.
Disulfide bonds in templates are numbered according to occurrence in the sequences and corresponding cysteine pairs in the models are numbered
with respect to the template numbering.
doi:10.1371/journal.ppat.0040042.g001
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further investigate the quality of the models by inspecting
them for conserved residues stabilizing the determined
structures of EBA-175 and Pka-DBL domains.
Structural alignment of the EBA-175 and Pka-DBL
domains identiﬁed a number of positions, which can be
assumed to be important for the stabilization of the DBL fold
(Table S2). The positions of these residues were distributed
throughout the domains in blocks. We then made a multiple
structural alignment including the six VAR2CSA DBL models
and the EBA-175 and Pka-DBL structure to identify
VAR2CSA residues at the positions corresponding to the
positions identiﬁed as conserved and stabilizing EBA-175 and
Pka-DBL (Figure 2). This analysis showed that a high number
of hydrophobic positions forming a hydrophobic core in the
DBL structure were conserved in the models, together with
positions of helix capping and positions of interacting buried
polar residues (Table S2 and Figure 2). This conservation of
stabilizing positions indicates that the alignments of the
model sequences to the template sequences are correct in
regions surrounding these positions. Additionally, we found
that most template-stabilizing positions are located in semi-
conserved blocks reported in an analysis of 106 VAR2CSA
sequences [19] (data not shown), which suggests that these
stabilizing positions in the templates are conserved in
VAR2CSA to stabilize the folding of the VAR2CSA DBL
domains in general. The structural alignment and sequence
alignments used by HHpred for modeling were analyzed for
conservation of cysteines forming disulﬁde bonds in the
template DBL structures. The models of the VAR2CSA DBL
domains all contain conserved cysteine positions likely to
form disulﬁde bonds (Figures 1 and 2). The disulﬁde bonds
Figure 2. A Structural Alignment of the Template Structures EBA-175 F1 and F2 and Pka-DBL and the Six VAR2CSA DBL Models
Vertical color bars denote positions of stabilizing residues in template structures. Blue bars denote cysteines forming disulfide bonds, green bars denote
buried hydrophobic residues, orange bars denote helix capping residues, and red bars denote buried polar/charged residues. The location of sub-
domains S1–S3 are marked by horizontal black bars, and regions of missing structural information in the template structures are marked by black
arrowheads. Residues involved in GAG binding of EBA-175 DBL domains or DARC receptor binding of Pka-DBL are marked with red letters. EBA-175
residues involved in dimerization are marked in blue letters.
doi:10.1371/journal.ppat.0040042.g002
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e42 0004
Structural Insight into Epitopes in VAR2CSAwere numbered according to the occurrence of the cysteines
in the sequence. Cysteines of disulﬁde bond 1 are conserved
in all models except DBL6. Likewise, the cysteines of disulﬁde
bond 5 are conserved in all models except DBL1.
A number of cysteines in the models are in close proximity
to a disulﬁde bond-forming template cysteine. This suggests
that the local alignments used for the modeling are sub-
optimal or that alternative disulﬁde bonds are formed in the
VAR2CSA DBL domains.
An interesting example is the disulﬁde bond 2 (Figure 1,
number 2 and Figure 2, positions 38 and 64). The disulﬁde
bond is proximal to a region containing glycan-binding
amino acids in the EBA-175 F1 and F2 domains (Figure 2,
positions 44, 48, and 50–53) and it may play a role for the
function of these domains. Among the VAR2CSA DBL
domains, only DBL3 has both cysteines conserved. None of
the other VAR2CSA DBL sequences have two cysteines in the
proximity, and it is thus unlikely that the apparent variation
stems from incorrect alignments. The lack of the disulﬁde
bonds in some regions of the VAR2CSA DBL domains may
suggest higher ﬂexibility and a more dynamic structure than
in DBL domains stabilized by a higher number of disulﬁde
bonds.
The analysis of different types of stabilizing characteristics
shows that these to a large extent are conserved between the
template and the VAR2CSA models. Since our aim was to
map experimental data onto the DBL models, rather than to
analyze the structural conformations in detail, we concluded
that the models were of sufﬁcient quality for mapping of
these data.
Modeling of VAR2CSA Inter-Domain 2
The extracellular part of VAR2CSA consists of six DBL
domains and a sequence stretch consisting of 337 amino acids
named inter-domain 2 (ID2) [9]. This part of the molecule has
attracted little attention and has been viewed as an inter-
domain spacer sequence. We analyzed the ID2 sequence
(PFL0030c positions 879-1216) for homology to other
proteins using the HHpred search and alignment tool.
Interestingly, the EBA-175 and Pka-DBL domains were all
identiﬁed as homologous to the ID2 domain with very high
HHpred probability scores (probabilities between 98.3% to
99.9%). The similarity was pronounced in a region of 100
residues (PFL0030c positions 1017–1116), which aligned to
the ﬁrst two a-helices in S3 with a sequence identity of 19.8%.
Using the EBA-175 F2 DBL domain as template, we modeled
the structure of ID2 positions 1017–1116 (Figure 3A and 3B).
The secondary structure of the whole ID2 domain was then
predicted using PSIPRED (data not shown). The topology of
predicted secondary structure elements in the ID2 domain
suggested that the C-terminal part of ID2 has a similar fold to
DBL S3, but did not support the notion that the N-terminal
part of ID2 has a fold similar to DBL S1 and S2.
In most PfEMP1 molecules the ﬁrst DBL domains are
separated by a cysteine-rich inter-domain region (CIDR1) on
which there is no structural data available. Using the HHpred
server homology between CIDRs and EBA-175 was identiﬁed.
To identify the signiﬁcance of our results, and to make a
more general analysis, we used a number of CIDR domains
for the analysis. Since VAR2CSA ID2 and CIDR1 are placed
either after the ﬁrst or the second DBL domain and can be
divided into sub-groups, we examined CIDR1 sequences
representative for the three subgroups CIDR-alpha, beta
and gamma. Similarly to the ID2 domain, the homology was
detected in the ﬁrst two helices of the DBL S3 and a structure
model was made using the EBA-175 F2 DBL as template
structure (Figure 3B). The homologous region was part of the
CIDR M2 region deﬁned by Smith et al. [10]. Similarly to our
results of ID2, an analysis of topology in the predicted
secondary structure suggested that C-terminal structures of
CIDR domains are similar to the known structures of DBL S3
domains, but that the structure of the N-terminal may vary
from DBL domains. These predictions suggest that like ID2,
the C-terminal part of CIDR1 seems to form a structure
similar to that of the DBL S3.
Mapping Surface-Expressed Continuous Epitopes on
VAR2CSA
In rational PAM vaccine design, it is important to establish
which parts of native VAR2CSA are accessible to antibodies
acquired by women who have developed immunity to
pregnancy-associated malaria. Additionally, the cross-reac-
tivity of these antibodies is an important issue to investigate
because of the variability in VAR2CSA sequences. The latter
has been addressed in several studies which have been
investigating the cross-reactivity of naturally acquired human
antibodies between different P. falciparum lines. Both cross-
reactivity [25,26] and isolate-speciﬁc recognition of anti-
bodies have been reported [26,27]. These studies were based
on antibody reactivity to IE and the speciﬁcity as well as the
target of the cross-reactive and isolate-speciﬁc antibodies are
thus not known. In our study, we have instead used VAR2CSA
peptide arrays measuring binding to shorter peptides.
Anti-VAR2CSA IgG from pools of plasma was absorbed
using VAR2CSA-expressing IE and the antibody reactivity of
the pools in a VAR2CSA peptide array compared before and
after absorption [18]. Measuring the antibody reactivity in the
peptide assays allowed qualitatively mapping of surface-
exposed regions of the VAR2CSA DBL domains. Plasma
samples from 180 Tanzanian women, sampled at the time of
delivery, were tested for reactivity towards CSA binding
parasites (3D7CSA and FCR3CSA) in ﬂow cytometry and in
ELISA towards recombinant VAR2CSA protein. Two pools
Figure 3. Modeled Regions of ID2 and CIDR Domains
The S3 domain of the template EBA-175 F2 is shown in white. Cysteines
in the models are highlighted in red.
(A) The model of the VAR2CSA ID2 domain superimposed in yellow on
the EBA-175 F2.
(B) Similar to (A) except showing only the S3 domain.
(C) Model of a CIDR domain.
doi:10.1371/journal.ppat.0040042.g003
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anti-VARCSA IgG were made using plasma from 32 and 10
Tanzanian pregnant women, respectively. One of the plasma
pools (Human plasma pool 1) was depleted using erythrocytes
infected with 3D7CSA parasites. From the other pool (Human
plasma pool 2), two depleted plasma pools were generated by
depleting one part with erythrocytes infected with 3D7CSA,
and depleting the other part on erythrocytes infected with
the FCR3CSA parasite line. As a control, we depleted a pool
containing anti-VAR2CSA IgG (Human plasma pool 3) on a
3D7 parasite expressing a non-VAR2CSA PfEMP1 variant
(VAR4). The antibody assays were performed on an array
containing 442 overlapping 31mer peptides corresponding to
the extracellular part of VAR2CSA based on the sequence of
3D7.
Before absorption, we observed a number of intense peaks
for most of the domains (Figures S1–S6). The intensity varied
between domains, for instance, the peptide reactivity in DBL1
resulted in highly intense peaks, whereas the peptide activity
of DBL2 resulted in less intense peaks. The antibody
reactivity towards the majority of peptides was not affected
by the depletion; nevertheless depletion on native VAR2CSA
consistently removed antibody reactivity against some pep-
tides in all domains (Figures S1–S6). In general depletion on
the non-CSA binding parasite did not reduce anti-VAR2CSA
reactivity in the peptide array, but a small reduction of
peptide-speciﬁc reactivity was detected in regions for DBL2
and DBL4. For DBL4 there was an overlap in the depletion on
the non-CSA binding parasite and the CSA-binding parasite,
indicating that some of the surface-exposed parts identiﬁed
in DBL4 could be due to non-speciﬁc absorption.
In addition to the human plasma pool, a pool of sera from
six rabbits each immunized with a different VAR2CSA DBL
domain was absorbed and tested. The pattern of reactivity in
the peptide array with this pool before absorption was
slightly different from the reactivity obtained with the human
plasma pools and this difference was also reﬂected in the
absorption experiments.
Taken together these results indicated that all domains
including the N-terminal segment contained continuous
peptide sequences accessible to antibodies when the VAR2-
CSA protein was expressed on the surface of CSA-binding IE.
It was difﬁcult however, to detect a pattern for this reactivity
between the domains when depicting the reactivity on a
string of residues. We therefore went on to visualize the
reactivity on the DBL models.
3-D Aspects of Surface-Exposed Epitopes in VAR2CSA DBL
Domains
To facilitate the mapping of depleted regions from the
peptide array data we calculated depletion values (DV) by
subtracting the depleted reactivity from the non-depleted
reactivity. DV were calculated for each of the four depletion
experiments (human pool 1 versus 3D7 or FCR3, human pool
2 versus 3D7, rabbit pool versus 3D7) and mapped onto the
six structural DBL models (Figures S7–S11). Figure 4 shows
the results for DBL6 and it is apparent that the depletion
experiments using the two human plasma pools identiﬁed
essentially the same regions as target for surface reactive
antibodies (Figure 4A versus 4B). The results obtained in the
absorption experiment using FCR3-infected erythrocytes
gave essentially the same results as the experiment using
3D7-infected cells (Figure 4B versus 4C). Since the peptide
array was based on the 3D7 sequence this indicates that the
surface-exposed epitopes on the 3D7 and FCR3 versions of
VAR2CSA are cross-reactive or target-conserved epitopes.
The absorption experiment using the rabbit plasma pool only
showed depletion of antibodies targeting peptides residing in
S1 and S2 (Figure 4D). There was no indication of depletion
of antibodies targeting S3 in any of the experiments. To
facilitate a comparison between the DBL domains, and to
reduce the risk of false positive DV, we created consensus DVs
for each domain by calculating a sum of normalized DV from
each of the four absorption experiments and scoring the
residue as positive if the value was above a ﬁxed threshold
(Figure 5). Overall there was agreement between the models
based on the individual absorption experiments and the
consensus DV (Figure 4A and 4B versus Figure 5, DBL6). The
results for DBL3 were also in agreement with the surface-
Figure 4. Mapping of Surface-Exposed Antibody-Reactive Regions onto
the Model of the DBL6 Domain
The color intensity denotes the level of antibody depletion when
VAR2CSA containing plasma is incubated with parasites expressing
native VAR2CSA. The following plasma and parasite combinations were
used for the depletion experiments.
(A) Human plasma pool 1 depleted with 3D7 parasites.
(B) Human plasma pool 2 depleted with 3D7 parasites.
(C) Human plasma pool 2 depleted with FCR3 parasites.
(D) Rabbit plasma pool depleted with 3D7 parasites.
doi:10.1371/journal.ppat.0040042.g004
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the consensus models it should be kept in mind that surface-
exposed VAR2CSA regions can only be detected if the plasma
pool contains antibodies against these regions and if the
antibodies can be detected in the peptide array assay. Thus,
regions which are not targeted by antibodies, or regions
targeted by antibodies that cannot be detected in the peptide
array experiment (because they either target non-linear
sequences or polymorphic sequences not represented in
3D7 VAR2CSA,) will not be scored as surface reactive. As a
consequence this method will only map a certain proportion
of epitopes. Likewise, residues buried in the native molecule
but residing close to a region representing a surface-exposed
epitope on the peptides will score as positive.
When comparing the consensus models for the six DBL
domains, it was evident that the pattern of reactivity was
comparable in DBL domains 1, 2, 3, 5, and 6, whereas the
pattern in DBL4 was unique (Figure 5). For the former
domains the targets of surface-reactive antibodies were
mainly located in S1 and S2, whereas little reactivity was
found in S3, which is located on the lower left side of the
models in Figure 5. In S1 and S2 both loops and a-helices
were targets of surface reactive antibodies. The loop between
S1 and S2 (Figure 2 positions 81–87 and appearing most
prominently in the upper left corner of the DBL2 model on
Figure 5) is ﬂexible in the Pka-DBL structure and we observe
a high sequence variation between the DBL domains in the
region, suggesting that the corresponding loops in the
VAR2CSA DBL domains are ﬂexible, and reinforcing the
possibility that VAR2CSA domains can be divided into sub-
domains. In DBL domains 2, 3, 5, and 6, a loop in S2
(appearing most prominently in the lower right corner of
DBL3 on Figure 5) was also targeted by surface reactive
antibodies. A loop region in S1 (Figure 2, positions 44–52,
appearing most prominently in the center of DBL6 on Figure
5) was recognized in DBL domains 1, 2, 3, and 6. Interestingly,
the corresponding regions in EBA-175 contain glycan-bind-
ing residues. The S2 a-helix appearing in the upper right on
all models was recognized in all domains but DBL4, whereas
some of the other a-helices in S1 and S2 were recognized to a
varying degree.
The regions of DBL4 targeted by surface-reactive anti-
bodies differed markedly from the other domains. Relatively
more reactivity was detected against S3 and the reactivity
against S2 was mainly against regions on opposite side of the
domain compared to the other domains (Figures 5 and 6).
The possibility that DBL4 is positioned different from the
other domains in the quaternary VAR2CSA structure is in
agreement with the ﬁnding that the DBL4-speciﬁc rabbit
antibodies are not reacting with the native VAR2CSA on IE
([28] and unpublished data). The different pattern of DBL4
recognition could also be explained by the fact that some
antibodies targeting DBL4 peptides were non-speciﬁcally
absorbed on IE (Figure S4, lower panel).
Figure 5. Areas Predicted to be Targeted by Surface-Reactive Antibodies on the Six VAR2CSA DBL Domains
The highlighted regions were defined on the basis of the results of several experiments where anti-VAR2CSA antibody containing plasma was
incubated with parasites expressing native VAR2CSA. Residues with consensus DVs . 1 which are conserved in sequences of VAR2CSA are highlighted
in blue, and variable residues with consensus DVs.1 are highlighted in green. See text for details. The positions of DBL3 and DBL5 peptides (P62 and
P63 respectively) used for affinity purifying IgG (see Figure 8) are marked with black arrows.
doi:10.1371/journal.ppat.0040042.g005
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Structural Insight into Epitopes in VAR2CSAThere is no evidence that S3 is undergoing less diversifying
selection, which might be expected considering the present
experimental data. To address whether epitopes in S3 in
particular are conformationally arranged compared to S1þS2
and thus showing a bias in the results, we afﬁnity puriﬁed
rabbit antibodies on monomeric recombinant DBL2 and
assessed these antibodies on the peptide array. We found that
epitopes in both S2 and S3 could be detected by the peptide
array analysis (data not shown), indicating that the system was
functioning for epitopes in S3 as well.
Using a multiple sequence alignment of seven full-length
VAR2CSA sequences, residues were classiﬁed as conserved if
they were all identical and as polymorphic if any of the
sequences showed variation in the particular position. It is
apparent from Figures 5 and 6 that all domains contained
both conserved and polymorphic regions targeted by surface
reactive antibodies, but the conserved regions were most
prominent in DBL3 and DBL5. This is in agreement with data
showing that antibodies raised against recombinant proteins
representing DBL3 and DBL5 are more likely to cross-react
with heterologous parasites, than antibodies raised against
the other domains [28]. Furthermore, these ﬁndings also
support data showing that antibodies raised against one
DBL3 or DBL5 variant are highly cross-reactive with a large
panel of placental isolates (Magistrado et al., submitted).
Finally, the data is also in agreement with the reactivity of
human monoclonal antibodies produced by immortalized B
cells from malaria-exposed pregnant women which are
directed predominantly against these two domains [29].
Conserved Surface-Exposed VAR2CSA Epitopes
To further investigate the presence of conserved immuno-
genic epitopes in VAR2CSA domains, we performed com-
petition ELISA using a large panel of recombinant VAR2CSA
DBL3 domains derived from placental isolates [18]. One
variant of VAR2CSA DBL3 was coated in ELISA plates and
the antibody reactivity of a high-titered VAR2CSA plasma
pool was compared before and after pre-incubation with a
competing VAR2CSA DBL3 variant. By this method it was
possible to quantify the relative level of variant-speciﬁc IgG
towards individual DBL3 variants. As positive and negative
controls we incubated the plasma pool with homologous
VAR2CSA DBL domain or VAR2CSA DBL5 domain as
competing antigen (Figure 7). Pre-incubation with non-
homologous DBL3 domain reduced the reactivity by 25%–
100%. No competition/absorption was seen with the control
proteins. These data strongly suggest that the insect-cell
produced DBL3 domains share common and cross-reactive
motifs.
To determine whether some of these conserved linear
regions were exposed on the surface of the native parasite
protein, we synthesized peptides corresponding to two
regions in DBL3 and DBL5 suggested by the peptide array
data to be surface-exposed (Figure 5). The ﬁrst peptide P62,
corresponded to aa position 1350–1370 in DBL3. This region
is highly conserved having only one variant aa (based on
alignment of 43 VAR2CSA DBL3 sequences). The second
peptide, P63, corresponds to aa 2045–2061 in DBL5 and is
also relatively conserved having 2 variant aminoacids out of
17 (based on alignment of 15 VAR2CSA DBL5 sequences).
P62 and P63 were tested in ELISA for reactivity with
Tanzanian male and female plasma and both showed
signiﬁcantly higher reactivity with female plasma as com-
pared to male plasma (Mann-Whitney rank sum test, p , 0.05;
data not shown). The two peptides were screened in ELISA
for reactivity against plasma from rabbits immunized with
recombinant DBL3 or DBL5 protein and peptide-reactive
rabbit sera was used to afﬁnity purify antibodies on the
peptides to create peptide-speciﬁc IgG reagents. The afﬁnity-
puriﬁed antibodies were subsequently assayed in ﬂow
cytometry for reactivity with native VAR2CSA expressed on
erythrocytes infected with CSA-binding 3D7 or FCR3 strain
(Figure 8). Both the DBL3 and DBL5 peptide puriﬁed
antibodies reacted strongly with FCR3CSA strain and to
lesser extend with the 3D7CSA parasite. The DBL5 peptide
antibodies were afﬁnity-puriﬁed from a rabbit immunized
with a FCR3 DBL5 domain, and the difference of two amino
acids in the peptide sequence could explain the lower
reactivity with 3D7CSA compared with FCR3CSA. The
DBL3 peptide-speciﬁc antibodies were afﬁnity puriﬁed from
a rabbit immunized with a placental variant of DBL3 protein
and there is only one amino acid differing between this
placental sequence and the FCR3 and 3D7 sequences. It was
intriguing to ﬁnd that the afﬁnity-puriﬁed antibodies
recognized the parasites to varying degree. One reason for
this could be a difference in levels of VAR2CSA protein
expressed on 3D7 and FCR3, or the observed difference could
be accounted for by the single polymorphisms in the peptide
sequences. A third explanation could be that polymorphic
ﬂexible loop regions, ﬂanking the conserved surface exposed
parts, inﬂuence the accessibility of the surface-exposed
regions to varying degrees between 3D7 and FCR3.
Conserved surface-exposed epitopes appear to be attrac-
tive vaccine targets. However, protective immunity is
acquired through successive pregnancies [6,30], and is a
function of transmission intensity [31]. Naturally acquired
protection could therefore depend on the ability to recognize
several polymorphic VAR2CSA variants. This is consistent
with the ﬁnding that some targets of naturally acquired
Figure 6. VAR2CSA DBL4 Regions Predicted to be Targeted by Surface-
Reactive Antibodies
The plot is similar to Figure 4, except viewed from the reverse side.
doi:10.1371/journal.ppat.0040042.g006
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Structural Insight into Epitopes in VAR2CSAantibodies are under diversifying selection [18]. The levels of
antibodies against pregnancy-associated parasite-encoded
antigens on the surface of the erythrocyte increase with the
number of pregnancies, and are correlated to the adhesion
inhibitory capacity [7,32]. Therefore, our identiﬁcation of
antibody binding parts in more conserved regions of
VAR2CSA may seem like a paradox. However, there could
be several explanations for this ﬁnding: Firstly, the identiﬁed
regions may have importance for the function of VAR2CSA,
and this could lead to conservation. Second, the conserved
regions may be less immuno-dominant than other more
variable regions of VAR2CSA. This would make the develop-
ment of antibodies directed against these regions less
frequent, and result in a delay in the development of
immunity. Finally, whole antibody binding surfaces may be
composed of both conserved and variable regions, where the
variance of a few residues would be enough to disrupt the
binding. Most antibody binding epitopes of globular proteins
have been estimated to be discontinuous in nature [33], and
additionally it has been shown that most discontinuous
epitopes are comprised by 14–19 amino acids, including a
linear segment of 4–7 amino acids [34]. Therefore, the
complete binding surface of antibodies recognizing P62 or
P63 could very likely be discontinuous, and comprised by
both polymorphic and more conserved regions.
We have identiﬁed conserved VAR2CSA regions targeted
by antibodies recognizing the surface of IE. Furthermore we
have been able to induce rabbit antibodies against these
regions by immunization with recombinant DBL domains.
This is a promising ﬁnding for vaccine development and it
will be important to establish whether antibodies against
conserved surface-exposed VAR2CSA regions can inhibit the
binding of parasites to CSA.
VAR2CSA, a Globular Protein?
So far, little is known about the overall structure of
VAR2CSA or any other PfEMP1. It has been suggested that
the PfEMP1 protein architecture is comprised by a compact
semi-conserved head structure which largely deﬁnes the
binding afﬁnity and a number of variable C terminal domains
[12]. Previous data have indicated that the general DBL fold is
relatively conserved [14,16,18,35] and that DBL domains can
interact with each other as building blocks to form binding
sites [14]. The data presented here indicate that DBL S3 is less
surface-exposed than S1 and S2. Sub-domain 3 contains two
long a-helices which are conserved in the template structures.
A number of multimeric protein complexes have been
reported to be stabilized by interactions between long a-
helices; a well-studied example is the trimer of inﬂuenza virus
hemagglutinin [36]. The data presented here does not lend
support to the idea of a compact conserved head structure in
VAR2CSA. Rather it is tempting to propose models of
Figure 7. A Matrix Showing the Level of Cross-Reactive Antibody Targets between 22 Placental VAR2CSA DBL3 Variants Produced in Baculovirus-
Infected Insect Cells
Cross-reactivity was determined by competition ELISA using a Tanzanian female plasma pool with a high titer of VAR2CSA-specific antibodies.
Responses with the same protein as the competing and coating antigen are shown in the diagonal. Blanks with no square are protein combinations not
tested. The identity of the various DBL3 proteins corresponds to the nomenclature used in the published multiple sequence alignment [18]. Control
proteins included a DBL5 VAR2CSA protein and a non-VAR2CSA DBL domain (PFD1235w).
doi:10.1371/journal.ppat.0040042.g007
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Structural Insight into Epitopes in VAR2CSAVAR2CSA where a-helices of different DBL domains interact
to bury a considerable part of S3 in the interface between the
domains. The interaction could be formed between DBL
domains of a single VAR2CSA molecule to form a more
globular shape of VAR2CSA. Another possibility is that
several VAR2CSA molecules form dimers or multimers with
S3 buried in the middle. These models do not exclude the
possibility that the ﬂexible loop regions, also present in S3,
protrude from the compact core structure of the protein [29],
however we were not able to measure antibodies to these
regions using the peptide array. The hypothesis that
VAR2CSA is present as a globular protein opens up for the
possibility that the CSA binding site is comprised of regions
from different DBL domains, like the glycan binding sites of
EBA-175 [14]. Further exploration of the quaternary struc-
ture of VAR2CSA is therefore of the utmost importance.
Materials and Methods
Modeling the structure of the VAR2CSA domains. Structures of the
CIDR domains and the 3D7 VAR2CSA DBL and ID2 domains were
modeled using the HHpred server with default settings [20]. The
HHpred method is based on comparisons and alignments of hidden
Markov models (HMMs), which include gaps and insertion proba-
bilities. The modeling of the DBL3 domain was done as described
previously [18]. VAR2CSA domains were modeled separately by
splitting the PFL0030c sequence into separate domains (DBL1 aa 57–
400, DBL2 aa 531–879, DBL4 aa 1575–1911, DBL5 aa 1999–2283,
DBL6 aa 2340–2633, ID2 aa 879-1216). All HMM databases available
in web-server were used for template structure search, including the
Protein Data Bank (PDB). For all the VAR2CSA DBL domains
described, the structures of the EBA-175 DBL domains [14] and the
Pka-DBL domain [16] had HHpred probability scores signiﬁcantly
higher than other structures detected. The DBL structure with the
highest sequence and secondary structure alignment scores were
chosen as template for each domain. Template alignments proposed
by the HHpred method were used to generate 3D models by using a
HHpred server toolkit protocol for MODELLER [37]. Models were
evaluated using Verify3d [24] and ANOLEA [23], available in the
HHpred server toolkit. Superimpositions of EBA-175 F1, F2, Pka-
DBL and VAR2CSA domains were made using the MAMMOTH
multi-alignment server [38]. NACCESS version 2.1.1 [39] was used for
analysis of relative accessible surface areas (RSAs) in the template
structures. Residues with RSA , 30% were considered buried.
Separate secondary structure predictions of CIDR and ID2 were
made using the PSIPRED [22]. All structural visualizations were
produced using PyMol [40].
Selection and depletion of plasma samples on parasites. Plasma
samples sampled at the time of delivery from Tanzanian woman were
tested in ﬂow cytometry for the presence of antibodies against CSA
binding parasites. Positive samples were selected for further analysis
in ELISA; plasma levels of DBL1-DBL6 VAR2CSA speciﬁc IgG were
measured in standard ELISA assays [41]. Plasma samples positive
against more than two domains were used to make two pools of
plasma samples. No single plasma sample was used in both pools.
Plasma originated from women with different parities ranging from
one to seven. The control human plasma pool 3 was a hyperimmune
pool made from 7 Tanzanian women and 3 male. For testing the
recognition pattern of the two synthetic peptides P62 and P63 we
used a panel of Tanzanian female plasma which was selected on the
basis of having high levels of antibodies towards CSA binding
parasites and as controls we used Tanzanian male plasma. In addition
we tested this panel of male and female plasma for reactivity to
GLURP protein to ensure that we were not merely measuring
Figure 8. Surface Reactivity (Fitch FL1) of Rabbit Antibodies Targeting
Conserved VAR2CSA Regions
Rabbit antibodies were affinity purified on peptides (P62 and P63; see
Figure 5 for details) and tested for reactivity with IE expressing VAR2CSA.
The parasite lines FCR3CSA (A) and 3D7CSA (B) IE were used. The
following antibodies were used: grey, IgG control; red, VAR2CSA-specific
rabbit pool; blue, P63 (DBL5)-specific antibodies; green, P62 (DBL3)-
specific antibodies. For FCR3, the number of cells staining positive with
the VAR2CSA pool, P63 and P62 were 97%, 56%, and 48%, respectively.
For 3D7, 85%, 7%, and 6% of the cells were positive.
doi:10.1371/journal.ppat.0040042.g008
PLoS Pathogens | www.plospathogens.org February 2008 | Volume 4 | Issue 2 | e42 0010
Structural Insight into Epitopes in VAR2CSAdifferent levels of malaria exposure. Rabbits were immunized with
DBL1–DBL6 and ID2 recombinant protein as described [42] and the
seven serum samples were pooled to create the VAR2CSA rabbit
pool.
3D7 and FCR3 parasites were panned on BeWo cells to create CSA
adhering parasite lines. Using real time PCR and ﬂow cytometry with
VAR2CSA speciﬁc reagents as well as plasma from Tanzania, we
veriﬁed that the parasites were gender-speciﬁcally recognized and
expressing high levels of VAR2CSA on the surface of the infected
erythrocyte [43]. Ethical clearance for collection of plasma samples
was given by the Tanzanian health authorities.
For the parasite IgG depletion 40 ll of the plasma pool were
incubated with 2.0310
8 MACS puriﬁed intact late stage trophozoite-
and schizont-IE for 20 min at 4 8C. Hereafter, the cells were
centrifuged at 800g for 8 min, and the supernatant used to suspend a
new pellet of 2.0 3 10
8 infected erythrocytes. This procedure was
repeated four times. Depletion on parasites was performed sequen-
tially until iRBC reactivity could not be reduced further as
determined by ﬂow cytometry (see Figure S12).
Analysis of Pepscan data. A Pepscan array containing 442 31mer
peptides corresponding to the extracellular part of 3D7 VAR2CSA
was used for antibody binding studies. The sequences of the peptides
had an overlap of six residues and the purity of the peptides was
expected to be 70% or higher. All Pepscan data were analyzed for
short motifs to derive the activity of single residues as described
previously [18]. The use of the motif analysis ensured that reactivities
of single residues were derived from several peptides in order to take
effects of possible impurities into account.
As part of the motif analysis, the data from each individual
experiment were normalized based on the average activity measured
for the total array. This was done to avoid experimental errors caused
by inter-assay variation. However, this procedure caused peaks
remaining after depletion to gain intensity, because the depletion
of other peaks lowered the general average of the data. Care was
taken to avoid mis-interpretations of data caused by a gain in
intensity upon depletion. For each of the four depletion studies, DVs
were calculated by subtracting depleted Pepscan data points from
non-depleted points. Peaks that have a diminished intensity after
depletion lead to positive DVs. Therefore only positive DVs of each
individual experiment were split into ﬁve equally sized intervals
ranging from the highest to the lowest DVs and with increasing color
intensity. The ﬁve intervals were then plotted on the models. For
consensus DVs, the DVs for each depletion study on individual DBL
domain were ﬁrst normalized by subtracting the mean and dividing
with the standard deviation. Subsequently, the consensus DVs was
calculated by summing the normalized values for each position in the
DBL domains. Consensus DVs . 1 were plotted on the models as this
threshold ensured that only the peaks with the highest consensus DVs
were included.
Production of recombinant proteins and competition ELISA. All
VAR2CSA DBL3 constructs derived from placental isolates were
cloned and sequenced as described elsewhere [18] and the DBL5d
domain of PFD1235w was cloned as described in [44]. The DBL5
domain of VAR2CSA was ampliﬁed from genomic FCR3 DNA with
following primers: 59 CC CCC GGG AGA TGT TTT GAT GAT CAG
ACA and 39 ATT TGC GGC CGC CAT TAC CTT TAT CAT ACT C
and cloned into the pAcGP67-A vector as described for the DBL3
constructs. Recombinant Baculovirus particles were generated in Sf9
insect cells by co-transfecting with pAcGP67-A and linearized
Bakpak6 Baculovirus DNA (BD Biosciences). Recombinant constructs
were puriﬁed on a HIS-Select Nickel Afﬁnity Gel (H8286, SIGMA) as
secreted histidine-tagged proteins from the supernatant of virus-
infected High-Five insect cells.
Prior to competition ELISA, all DBL3 constructs and the DBL5e of
VAR2CSA were tested in indirect ELISA for antibody reactivity by
the female plasma pool (diluted 1:100) of 10 Tanzanian women
(Korogwe, mixture of primi- and multigravidae, selected based on
their high anti-VAR2CSA titers in ﬂow cytometry) and OD490 values
ranged from 1.3 to 3.2.
MaxiSorp microtiter plates (Nunc) were coated with antigen (1.5
lg/ml in PBS) overnight at 4 8C. The female plasma pool (diluted
1:100) was pre-absorbed with competing antigen (1 lg/ml) for 2 h at
room temperature (RT). After incubating the plates with blocking
buffer (PBS, 0.5 M NaCl, 1% Triton X-100, 1% BSA) for 1 h at RT, the
pre-absorbed pool was added to the antigen-coated wells in triplicate
and incubated for 1 h at RT. In addition to the pre-absorbed plasma
pool (pP), a non-absorbed pool (P) was included for each coating
antigen. Following washing of the plates four times with washing
buffer (PBS, 0.5 M NaCl, 1% Triton X-100, pH 7.4), the secondary
antibody (rabbit anti-human IgG HRP, P0214, Dako, Denmark)
diluted 1:3000 in blocking buffer was added and incubated for 1 h
at RT. Plates were again washed four times and antibody reactivity
visualized by the addition of o-phenylenediamine substrate. Color
reactions were stopped by the addition of 2.5 M H2SO4 and OD was
measured at 490 nm. The percent reduction in antibody reactivity
was calculated as follows: 100*[1-ODpP/ODP].
Peptides and afﬁnity puriﬁcation of antibodies. Peptide synthesis
was done at Sigma Genosys at at X . 70% purity. Two conserved,
surface-exposed regions were synthezised: P62-DBL3 YKNMILGTSV-
NIYEYIGKLQ residing at aa position 1350–1370 in the 3D7 sequence
and P63-DBL5 RIVRGPANLRNLKEFKE residing at aa position 2045–
2061.
Afﬁnity puriﬁcation of antibodies was done using HiTrap NHS-
activated HP columns (GE Healthcare, http://www.gehealthcare.com/)
according to the manufacturer’s instructions. In brief, 1.5 mg of
synthetic peptide (Sigma-Genosys) was dissolved in 0.2 M NaHCO3,
0.5 M NaCl (pH 8.3), and applied to the 1 ml column that had been
equilibrated with 3 3 2m l48C 1 mM HCl. After coupling, the
columns were washed alternating 0.5 M ethanolamine, 0.5 M NaCl
(pH 8.3) and 0.1 M acetate, 0.5 M NaCl (pH 4), followed by a ﬁnal wash
with PBS (pH 7.4). Before afﬁnity puriﬁcation, the peptides were
tested for reactivity against a panel of rabbit sera immunized with
different recombinant DBL domains. A rabbit plasma sample
reacting with one peptide was chosen to afﬁnity purify antibodies
speciﬁc for that peptide. Serum from a rabbit immunized with a
placental DBL3 variant (accession number ABK91125) was used to
afﬁnity purify on P62 and serum from a rabbit immunized with DBL5
FCR3 was used to afﬁnity purify antibodies on P63. Rabbits
immunized with the 3D7 VAR2CSA DBL3 and DBL5 protein did
not have antibodies against the peptides. 1 ml of rabbit plasma was
diluted in PBS (1:2), ﬁltered through a 0.45-lm ﬁlter and applied to
the column at a ﬂow rate of 0.5 ml / min. After washing the column in
5 ml PBS, afﬁnity-bound antibodies were eluted in fractions with a
total volume of 3.2 ml of 0.1 M glycine-HCl (pH 2.8) and neutralized
in 1 M Hepes (pH 8).
The speciﬁcity of the puriﬁed antibodies was tested in ELISA
against (1) the peptide used for afﬁnity puriﬁcation (2) the
recombinant DBL domain used to immunize the rabbit that provided
the plasma (3) another VAR2CSA domain.
Supporting Information
Figure S1. Plots of Pepscan Analysis Results for the DBL1 Domain
The top ﬁgure represents results from anti-VAR2CSA antibody
human plasma pool 1 before and after depletion with infected
parasites. The second ﬁgure from the top represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and
the third ﬁgure from the top represents similar results obtained by
using a rabbit anti-VAR2CSA antibody plasma pool. The bottom
ﬁgure shows the control human plasma pool 3, which was depleted
using a non-CSA binding parasite.
Found at doi:10.1371/journal.ppat.0040042.sg001 (68 KB EPS).
Figure S2. Plots of Pepscan Analysis Results for the DBL2 Domain
The top ﬁgure represents results from anti-VAR2CSA antibody
human plasma pool 1 before and after depletion with infected
parasites. The second ﬁgure from the top represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and
the third ﬁgure from the top represents similar results obtained by
using a rabbit anti-VAR2CSA antibody plasma pool. The bottom
ﬁgure shows the control human plasma pool 3, which was depleted
using a non-CSA binding parasite.
Found at doi:10.1371/journal.ppat.0040042.sg002 (69 KB EPS).
Figure S3. Plots of Pepscan Analysis Results for the DBL3 Domain
The top ﬁgure represents results from anti-VAR2CSA antibody
human plasma pool 1 before and after depletion with infected
parasites. The second ﬁgure from the top represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and
the third ﬁgure from the top represents similar results obtained by
using a rabbit anti-VAR2CSA antibody plasma pool. The bottom
ﬁgure shows the control human plasma pool 3, which was depleted
using a non-CSA binding parasite.
Found at doi:10.1371/journal.ppat.0040042.sg003 (69 KB EPS).
Figure S4. Plots of Pepscan Analysis Results for the DBL4 Domain
The top ﬁgure represents results from anti-VAR2CSA antibody
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Structural Insight into Epitopes in VAR2CSAhuman plasma pool 1 before and after depletion with infected
parasites. The second ﬁgure from the top represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and
the third ﬁgure from the top represents similar results obtained by
using a rabbit anti-VAR2CSA antibody plasma pool. The bottom
ﬁgure shows the control human plasma pool 3, which was depleted
using a non-CSA binding parasite.
Found at doi:10.1371/journal.ppat.0040042.sg004 (68 KB EPS).
Figure S5. Plots of Pepscan Analysis Results for the DBL5 Domain
The top ﬁgure represents results from anti-VAR2CSA antibody
human plasma pool 1 before and after depletion with infected
parasites. The second ﬁgure from the top represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and
the third ﬁgure from the top represents similar results obtained by
using a rabbit anti-VAR2CSA antibody plasma pool. The bottom
ﬁgure shows the control human plasma pool 3, which was depleted
using a non-CSA binding parasite.
Found at doi:10.1371/journal.ppat.0040042.sg005 (60 KB EPS).
Figure S6. Plots of Pepscan Analysis Results for the DBL6 Domain
The top ﬁgure represents results from anti-VAR2CSA antibody
human plasma pool 1 before and after depletion with infected
parasites. The second ﬁgure from the top represents similar results
obtained by using anti-VAR2CSA antibody human plasma pool 2, and
the third ﬁgure from the top represents similar results obtained by
using a rabbit anti-VAR2CSA antibody plasma pool. The bottom
ﬁgure shows the control human plasma pool 3, which was depleted
using a non-CSA binding parasite.
Found at doi:10.1371/journal.ppat.0040042.sg006 (61 KB EPS).
Figure S7. Mapping Surface-Exposed Antibody-Reactive Regions on
the Model of the DBL1 Domain
The color intensity denotes the values of positive depletion values.
(A) Human plasma pool 1 depleted with 3D7 parasites.
(B) Human plasma pool 2 depleted with 3D7 parasites.
(C) Human plasma pool 2 depleted with FCR3 parasites.
(D) Rabbit serum pool depleted with 3D7 parasites.
Found at doi:10.1371/journal.ppat.0040042.sg007 (2.5 MB TIF).
Figure S8. Mapping Surface-Exposed Antibody-Reactive Regions on
the Model of the DBL2 Domain
The color intensity denotes the values of positive depletion values.
(A) Human plasma pool 1 depleted with 3D7 parasites.
(B) Human plasma pool 2 depleted with 3D7 parasites.
(C) Human plasma pool 2 depleted with FCR3 parasites.
(D) Rabbit serum pool depleted with 3D7 parasites.
Found at doi:10.1371/journal.ppat.0040042.sg008 (2.8 MB TIF).
Figure S9. Mapping Surface-Exposed Antibody-Reactive Regions on
the Model of the DBL3 Domain
The color intensity denotes the values of positive depletion values.
(A) Human plasma pool 1 depleted with 3D7 parasites.
(B) Human plasma pool 2 depleted with 3D7 parasites.
(C) Human plasma pool 2 depleted with FCR3 parasites.
(D) Rabbit serum pool depleted with 3D7 parasites.
Found at doi:10.1371/journal.ppat.0040042.sg009 (2.8 MB TIF).
Figure S10. Mapping Surface-Exposed Antibody-Reactive Regions on
the Model of the DBL4 Domain
The color intensity denotes the values of positive depletion values.
(A) Human plasma pool 1 depleted with 3D7 parasites.
(B) Human plasma pool 2 depleted with 3D7 parasites.
(C) Human plasma pool 2 depleted with FCR3 parasites.
(D) Rabbit serum pool depleted with 3D7 parasites.
Found at doi:10.1371/journal.ppat.0040042.sg010 (2.4 MB TIF).
Figure S11. Mapping Surface-Exposed Antibody-Reactive Regions on
the Model of the DBL5 Domain
The color intensity denotes the values of positive depletion values.
(A) Human plasma pool 1 depleted with 3D7 parasites.
(B) Human plasma pool 2 depleted with 3D7 parasites.
(C) Human plasma pool 2 depleted with FCR3 parasites.
(D) Rabbit serum pool depleted with 3D7 parasites.
Found at doi:10.1371/journal.ppat.0040042.sg011 (2.5 MB TIF).
Figure S12. Depletion of Female Plasma on Infected Erythrocytes
A pool of female plasma was exposed to VAR2CSA expressing
erythrocytes infected with the 3D7 strain. The plasma pool was
sequentially exposed to four aliquots of MACS puriﬁed IE. In each
step 2310
 7 ll of plasma per infected cell was used, corresponding to
a total dilution of 5 3 10
 8 ll plasma/IE. The histograms show IgG
binding to infected erythrocytes stained with 5 ll plasma per 2310
5
cells. As secondary antibody 1.5 lg per 2310
5 IE of FITC conjugated
goat-anti human IgG (Beckman Coulter IM1627) was used. Grey,
blank control; red, female plasma pool (93% positive cells); blue,
depleted female plasma pool (11% positive cells).
Found at doi:10.1371/journal.ppat.0040042.sg012 (1.7 MB TIF).
Table S1. Modeling Details of the VAR2CSA DBL Domains
Found at doi:10.1371/journal.ppat.0040042.st001 (32 KB DOC).
Table S2. Summary of Conserved Stabilizing Positions in Models of
VAR2CSA DBL Domains
Found at doi:10.1371/journal.ppat.0040042.st002 (30 KB DOC).
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